Evaluation of Inflammation and Platelet Apoptosis Parameters in Obese Patients in Various Types of Anticoagulant Prophylaxis of Venous Thromboembolic Complications in Context of COVID-19

Abstract

INTRODUCTION: The physical inactivity, hypoventilation, as well as chronic inflammation in obese patients aggravates their condition in various diseases. These features have become important with the advent of the COVID-19 pandemic, in which inflammation and platelet-activated coagulopathy are closely linked.

AIM: To study laboratory parameters of inflammation and platelet apoptosis in obese patients using various types of anticoagulant prophylaxis of venous thromboembolic complications with the underlying COVID-19.

MATERIALS AND METHODS: The study included 370 patients with COVID-19. Depending on the presence or absence of obesity and the type of parenteral anticoagulant, patients in our study were divided into groups: group 1 — non-obese + low molecular weight heparin (LMWH) (n = 114), group 2 — non-obese + unfractionated heparin (UFH) (n = 58), group 3 — obesity + LMWH (n = 76), group 4 — obesity + UFH (n = 66). The incidence of venous thromboembolic complications (VTEC), bleeding, general markers of the acute phase of inflammation, and specific markers of platelet apoptosis (phosphatidylserine and calreticulin) have been analyzed.

RESULTS: At the end of hospital treatment, a decrease in ferritin levels was noted in patients both with and without obesity receiving LMWH. The concentration of calreticulin was higher in patients taking LMWH (groups 1 and 3). Phosphatidylserine levels were high in patients receiving LMWH only if they were obese. In patients taking UFH compared to LMWH, a high incidence of pulmonary embolism (PE) without a source (13.6% of cases versus 2.6%, respectively, p = 0.029) and PE with a source in the lower extremities (9.1% of cases versus 0%, respectively, p = 0.018) was found. When using LMWH, a lower incidence of bleeding was observed compared to using UFH (5.3% of cases versus 16.7%, respectively, p = 0.056).

CONCLUSION: The levels of phosphatidylserine and calreticulin are higher in obese patients receiving LMWH. At the same time, patients in this group have a low incidence of VTEC and hemorrhagic complications compared to the group of patients taking UFH.

Keywords

venous thrombotic complications / obesity / platelet apoptosis / phosphatidylserine / calreticulin

References

[1] Kalinin RE, Suchkov IA, Agapov AB. The Effectiveness of the Various Options of Anticoagulant Therapy for the Treatment of the Patients with Thrombosis of the Deep Veins of the Lower Extremities in the Routine Clinical Practice]. Flebologiya. 2017;(1):21–7. (In Russ). doi: 10.17116/flebo201711121-27

[2] Калинин Р.Е., Сучков И.А., Агапов А.Б. Эффективность различных вариантов антикоагулянтной терапии при тромбозе глубоких вен нижних конечностей в рутинной клинической практике // Флебология. 2017. № 1. С. 21–27. doi: 10.17116/flebo201711121-27

[3] Нeit JA, Spencer FA, White RH. The epidemiology of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):3–14. doi: 10.1007/s11239-015-1311-6

[4] Heit J.A., Spencer F.A., White R.H. The epidemiology of venous thromboembolism // J. Thromb. Thrombolysis. 2016. Vol. 41, No. 1. P. 3–14. doi: 10.1007/s11239-015-1311-6

[5] Kalinin RE, Suchkov IA, Agapov AB, et al. Analysis of Risk Factors of Venous Thromboembolic Complications and of Different Variants of Anticoagulant Therapy in Patients with New Coronavirus Infection. I. P. Pavlov Russian Medical Biological Herald. 2023;31(2):243–54. (In Russ). doi: 10.17816/PAVLOVJ110956

[6] Калинин Р.Е., Сучков И.А., Агапов А.Б., и др. Анализ факторов риска венозных тромбоэмболических осложнений и различных вариантов антикоагулянтной терапии у пациентов с новой коронавирусной инфекцией // Российский медико-биологический вестник имени академика И. П. Павлова. 2023. Т. 31, № 2. С. 243–254. doi: 10.17816/PAVLOVJ110956

[7] Mazzolai L, Ageno W, Alatri A, et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function. Eur J Prev Cardiol. 2022;29(8):1248–63. doi: 10.1093/eurjpc/zwab088

[8] Mazzolai L., Ageno W., Alatri A., et al. Second consensus document on diagnosis and management of acute deep vein thrombosis: updated document elaborated by the ESC Working Group on aorta and peripheral vascular diseases and the ESC Working Group on pulmonary circulation and right ventricular function // Eur. J. Prev. Cardiol. 2022. Vol. 29, No. 8. P. 1248–1263. doi: 10.1093/eurjpc/zwab088

[9] Borodina IA, Selezneva IA, Borisova OV, et al. Blood groups and secretory state in COVID-19. Nauka Molodykh (Eruditio Juvenium). 2021;9(4):589–96. (In Russ). doi: 10.23888/HMJ202194589-596

[10] Бородина И.А., Селезнева И.А., Борисова О.В., и др. Группы крови и секреторное состояние при COVID-19 // Наука молодых (Eruditio Juvenium). 2021. Т. 9, № 4. С. 589–596. doi: 10.23888/HMJ202194589-596

[11] Povarov VO, Kalinin RE, Mzhavanadze ND, et al. Risk Factors of Upper Extremity Deep Vein Thrombosis After Pacemaker Implantation. Flebologiya. 2023;17(4):312–9. (In Russ). doi: 10.17116/flebo202317041312

[12] Поваров В.О., Калинин Р.Е., Мжаванадзе Н.Д., и др. Факторы риска тромбоза глубоких вен верхних конечностей после имплантации электрокардиостимулятора // Флебология. 2023. Т. 17, № 4. С. 312–319. doi: 10.17116/flebo202317041312

[13] Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417–8. doi: 10.1016/s0140-6736(20)30937-5

[14] Varga Z., Flammer A.J., Steiger P., et al. Endothelial cell infection and endotheliitis in COVID-19 // Lancet. 2020. Vol. 395, No. 10234. P. 1417–1418. doi: 10.1016/s0140-6736(20)30937-5

[15] Platonova TA, Golubkova AA, Sklyar MS, et al. Clinical Manifestations of COVID-19 in Employees of Medical Organizations in the Early and Late Recovery Periods and Issues of Their Rehabilitation. Nauka Molodykh (Eruditio Juvenium). 2023;11(1):15–30. doi: 10.23888/HMJ202311115-30

[16] Платонова Т.А., Голубкова А.А., Скляр М.С., и др. Клинические проявления COVID-19 у сотрудников медицинских организаций в ранний и поздний восстановительный периоды и вопросы их реабилитации // Наука молодых (Eruditio Juvenium). 2023. Т. 11, № 1. С. 15–30. doi: 10.23888/HMJ202311115-30

[17] Zimmerman KA, Xing D, Pallero MA, et al. Calreticulin regulates neointima formation and collagen deposition following carotid artery ligation. J Vasc Res. 2015;52(5):306–20. doi: 10.1159/000443884

[18] Zimmerman K.A., Xing D., Pallero M.A., et al. Calreticulin regulates neointima formation and collagen deposition following carotid artery ligation // J. Vasc. Res. 2015. Vol. 52, No. 5. P. 306–320. doi: 10.1159/000443884

[19] Fischer CR, Mikami M, Minematsu H, et al. Calreticulin inhibits inflammation-induced osteoclastogenesis and bone resorption. J Orthop Res. 2017;35(12):2658–66. doi: 10.1002/jor.23587

[20] Fischer C.R., Mikami M., Minematsu H., et al. Calreticulin inhibits inflammation-induced osteoclastogenesis and bone resorption // J. Orthop. Res. 2017. Vol. 35, No. 12. P. 2658–2666. doi: 10.1002/jor.23587

[21] Wang L, Bi Y, Yu M, et al. Phosphatidylserine-exposing blood cells and microparticles induce procoagulant activity in non-valvular atrial fibrillation. Int J Cardiol. 2018;258:138–43. doi: 10.1016/j.ijcard.2018.01.116

[22] Wang L., Bi Y., Yu M., et al. Phosphatidylserine-exposing blood cells and microparticles induce procoagulant activity in non-valvular atrial fibrillation // Int. J. Cardiol. 2018. Vol. 258. P. 138–143. doi: 10.1016/j.ijcard.2018.01.116

[23] Vremennyye metodicheskiye rekomendatsii. Profilaktika, diagnostika i lecheniye novoy koronavirusnoy infektsii (COVID-19). Version 17 (14/12/2022) [Internet]. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf?1671088207. Accessed: 2024 May 06. (In Russ).

[24] Временные методические рекомендации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 17 (14.12.2022) [Интернет]. Доступно по: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/061/254/original/%D0%92%D0%9C%D0%A0_COVID-19_V17.pdf?1671088207. Ссылка активна на 06.05.2024.

[25] Schulman S, Kearon С; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. doi: 10.1111/j.1538-7836.2005.01204.x

[26] Schulman S., Kearon С.; Subcommittee on Control of Anti-coagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients // J. Thromb. Haemost. 2005. Vol. 3, No. 4. P. 692–694. doi: 10.1111/j.1538-7836.2005.01204.x

[27] Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5. doi: 10.1016/j.ijid.2020.03.017

[28] Yang J., Zheng Y., Gou X., et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis // Int. J. Infect. Dis. 2020. Vol. 94. P. 91–95. doi: 10.1016/j.ijid.2020.03.017

[29] Guan W–J, Ni Z–Y, Hu Y, et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. doi: 10.1056/nejmoa2002032

[30] Guan W.–J., Ni Z.–Y., Hu Y., et al.; China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China // N. Engl. J. Med. 2020. Vol. 382, No. 18. P. 1708–1720. doi: 10.1056/nejmoa2002032

[31] Simonnet A, Chetboun M, Poissy J, et al.; LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28(7):1195-9. doi: 10.1002/oby.22831

[32] Simonnet A., Chetboun M., Poissy J., et al.; LICORN and the Lille COVID-19 and Obesity study group. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation // Obesity (Silver Spring). 2020. Vol. 28, No. 7. P. 1195–1199. doi: 10.1002/oby.22831

[33] Kakkos S, Gohel M, Baekgaard N, et al. Editor’s Choice — European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc. 2021;61(1):9–82. doi: 10.1016/j.ejvs.2020.09.023

[34] Kakkos S., Gohel M., Baekgaard N., et al. Editor’s Choice — European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis // Eur. J. Vasc. Endovasc. 2021. Vol. 61, No. 1. P. 9–82. doi: 10.1016/j.ejvs.2020. 09.023

[35] Broni EK, Ogunmoroti O, Quispe R, et al. Adipokines and incident venous thromboembolism: The Multi-Ethnic Study of Atherosclerosis. J Thromb Haemost. 2023;21(2):303–10. doi: 10.1016/j.jtha.2022.11.012

[36] Broni E.K., Ogunmoroti O., Quispe R., et al. Adipokines and incident venous thromboembolism: The Multi-Ethnic Study of Athero-sclerosis // J. Thromb. Haemost. 2023. Vol. 21, No. 2. P. 303–310. doi: 10.1016/j.jtha.2022.11.012

[37] Bodary PF, Westrick RJ, Wickenheiser KJ, et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA. 2002; 287(13):1706–9. doi: 10.1001/jama.287.13.1706

[38] Bodary P.F., Westrick R.J., Wickenheiser K.J., et al. Effect of leptin on arterial thrombosis following vascular injury in mice // JAMA. 2002. Vol. 287, No. 13. P. 1706–1709. doi: 10.1001/jama.287.13.1706

[39] Payne GA, Borbouse L, Kumar S, et al. Epicardial Perivascular AdiposeDerived Leptin Exacerbates Coronary Endothelial Dysfunction in Metabolic Syndrome via a Protein Kinase C-β Pathway. Arterioscler Thromb Vasc Biol. 2010;30(9):1711–7. doi: 10.1161/ATVBAHA.110.210070

[40] Payne G.A., Borbouse L., Kumar S., et al. Epicardial Perivascular Adipose-Derived Leptin Exacerbates Coronary Endothelial Dysfunction in Metabolic Syndrome via a Protein Kinase C-β Pathway // Arterioscler. Thromb. Vasc. Biol. 2010. Vol. 30, No. 9. P. 1711–1717. doi: 10.1161/ATVBAHA.110.210070

[41] Gregson J, Kaptoge S, Bolton T, et al.; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol. 2019;4(2):163–73. doi: 10.1001/jamacardio.2018.4537

[42] Gregson J., Kaptoge S., Bolton T., et al.; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism // JAMA Cardiol. 2019. Vol. 4, No. 2. P. 163–173. doi: 10.1001/jamacardio.2018.4537

[43] Meng H, Kou J, Ma R, et al. Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation. Mol Med Rep. 2017;16(6):8579–88. doi: 10.3892/mmr.2017.7763

[44] Meng H., Kou J., Ma R., et al. Prognostic implications and procoagulant activity of phosphatidylserine exposure of blood cells and microparticles in patients with atrial fibrillation treated with pulmonary vein isolation // Mol. Med. Rep. 2017. Vol. 16, No. 6. P. 8579–8588. doi: 10.3892/mmr.2017.7763

[45] Althaus K, Marini I, Zlamal J, et al. Antibody-induced procoagulant platelets in severe COVID-19 infection. Blood. 2021;137(8):1061–71. doi: 10.1182/blood.2020008762

[46] Althaus K., Marini I., Zlamal J., et al. Antibody-induced procoagulant platelets in severe COVID-19 infection // Blood. 2021. Vol. 137, No. 8. P. 1061–1071. doi: 10.1182/blood.2020008762

[47] V’kovski P, Kratzel A, Steiner S, et al. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19:155–70. doi: 10.1038/s41579-020-00468-6

[48] V’kovski P., Kratzel A., Steiner S., et al. Coronavirus biology and replication: Implications for SARS-CoV-2 // Nat. Rev. Microbiol. 2021. Vol. 19. P. 155–170. doi: 10.1038/s41579-020-00468-6

[49] Antoniotti V, Bellone S, Gonçalves Correia FP, et al. Calreticulin and PDIA3, two markers of endoplasmic reticulum stress, are associated with metabolic alterations and insulin resistance in pediatric obesity: A pilot study. Front Endocrinol (Lausanne). 2022;13:1003919. doi: 10.3389/fendo.2022.1003919

[50] Antoniotti V., Bellone S., Gonçalves Correia F.P., et al. Calreticulin and PDIA3, two markers of endoplasmic reticulum stress, are associated with metabolic alterations and insulin resistance in pediatric obesity: A pilot study // Front. Endocrinol (Lausanne). 2022. Vol. 13. P. 1003919. doi: 10.3389/fendo.2022.1003919

[51] Wang J, Yu C, Zhuang J, et al. The role of phosphatidylserine on the membrane in immunity and blood coagulation. Biomark Res. 2022;10(1):4. doi: 10.1186/s40364-021-00346-0

[52] Wang J., Yu C., Zhuang J., et al. The role of phosphatidylserine on the membrane in immunity and blood coagulation // Biomark. Res. 2022. Vol. 10, No. 1. P. 4. doi: 10.1186/s40364-021-00346-0

RIGHTS & PERMISSIONS

Eco-Vector